A biweekly DPP ‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial
Year: 2024
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.16096
Authors: Qinghua He, Zhifeng Cheng, Yufeng Li, Xiaoyan Xing, Liping Li, Xinsheng Li, Junqing Zhang, Lingling Xu, Weihong Song, Fangqiong Li, Zhanhui Zhang, Lixin Guo
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Hospital, Fourth Affiliated Hospital of Harbin Medical University, Hebei Yanda Ludaopei Hospital, Henan University of Science and Technology, First Affiliated Hospital of Henan University of Science and Technology, Cangzhou Central Hospital, Peking University First Hospital, Peking Union Medical College Hospital, Chenzhou First People's Hospital, Haisco Pharmaceutical Group Co., Ltd. (China)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405023661